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Abstract
More than half of all colorectal carcinomas are known to exhibit an activated mitogen-activated protein kinase
pathway. The NF1 gene, a negative regulator of KRAS, has not previously been examined in a series of colorectal
cancer. In the present study, primary colorectal carcinomas stratified according to microsatellite instability status
were analyzed. The whole coding region of NF1 was analyzed for mutations using denaturing high-performance
liquid chromatography and sequencing, and the copy number alterations of NF1 were examined using multiple
ligation-dependent probe amplification and real-time polymerase chain reaction. The mutational hot spots in KRAS
and BRAF were sequenced, and promoter hypermethylation status of RASSF1A was assessed with a methylation-
specific polymerase chain reaction. One sample had two missense mutations in NF1, whereas nine additional tumors
had intronic mutations likely to affect exon splicing. Interestingly, 8 of these 10 tumors were microsatellite-unstable.
Four other tumors showed a duplication of NF1. Mutations in KRAS and BRAF were mutually exclusive and were
present at 40% and 22%, respectively. RASSF1A was hypermethylated in 31% of the samples. We show that the
RAS signaling network is extensively dysregulated in colorectal carcinomas, because more than 70% of the tu-
mors had an alteration in one or more of the four examined components.
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Introduction
Colorectal cancer (CRC) is one of the leading causes of cancer-related
deaths in the western world today, and at least 50% of CRCs are
thought to have a dysregulation of the RAS-RAF-MEK-ERK path-
way, also known as the mitogen-activated protein kinase (MAPK)
pathway [1]. When activated, this pathway leads to increased prolif-
eration and reduced apoptosis, two of six crucial abilities of a cancer
cell, as described by Hanahan and Weinberg [2]. There are several
components in this pathway, which, theoretically, could be affected
in cancer, and some are known mutational targets in cancer such as
KRAS and BRAF. KRAS has been widely established as an important
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oncogene since its first mutational report in 1984 [3], and it is now
known that it is mutated in 21% of all human sporadic cancers, in-
cluding one third of CRCs [1].2 BRAF was shown to be a mutational
target in cancer 5 years ago [4], and 20% of all human cancers har-
bors a mutation, including an estimated 13% of colorectal carcino-
mas.2 Another potential target of this pathway is the NF1 gene,
which encodes neurofibromatosis type 1, a GTPase-activating pro-
tein (GAP), governing hydrolysis of KRAS-GTP to KRAS-GDP
[5], thereby functioning as a negative regulator of KRAS signaling.
The NF1 gene is approximately 280 kb in size and maps to chromo-
some 17q11.2. It contains 61 exons, with an 11- to 13-kb transcript
and an open reading frame coding for 2818 amino acids. There are
two catalytical domains in NF1, which are important for its function,
namely, the cAMP/PKA domain comprising exons 11 to 17 and the
RAS-GRD (RAS GAP-related domain) domain comprising exons
21 to 27a [6–8]. Neurofibromatosis type 1, a dominant disorder,
is caused by mutations in NF1, but somatic mutations in this gene
can also contribute to tumorigenesis. Since the first mutation report
of the gene in 1992 showing that one colorectal tumor (of 22) was
mutated in NF1 [9], it has been speculated to play a role in colorectal
tumorigenesis. However, due to the large size of the gene and the
fact that there are no mutational hot spots, mutation analysis of
NF1 in tumors has been very scarce. RASSF1 (Ras association do-
main family 1) gene maps at chromosome 3p21.3, and its isoform
A (RASSF1A) has been found hypermethylated in 40% of lung tu-
mors [10] and in a large variety of human cancers, including CRC
[11,12]. As implied by its designation, RASSF1A is thought to in-
teract with KRAS through a Ras association domain that alters its
effects. RASSF1A has several effects, including promotion of apopto-
sis, cell cycle arrest, and maintenance of genomic stability, abilities
typical of tumor suppressor genes. Some of these effects refer to
the negative regulation of KRAS [13]. Its association to, and its effect
on, KRAS is still not solved, although increasing evidence points to a
direct binding between RASSF1A and farnesylated KRAS (reviewed
in the study of Donninger et al. [11]). The KRAS and BRAF muta-
tion status together with the alteration of other upstream compo-
nents affecting the RAS signaling have been reported for other
cancers [14], but only two previous studies have examined alterations
in KRAS, BRAF, and RASSF1A in the same series of colorectal neo-
plasms [15,16], and independent of cancer type, no previous study
has included a detailed analyses of the NF1 gene.
To provide further insight into the role of MAP kinase signaling in
CRC, we carried out the first comprehensive mutation analyses of
the NF1 gene in colorectal carcinomas in comparison with alterations
of BRAF, KRAS, and RASSF1A in a sample series selected to include a
comparable number of samples with and without the microsatellite
instability phenotype.
Materials and Methods
Tissue Specimen
Sixty-five sporadic colorectal carcinomas from 64 patients with a
mean age of 70 years (range 33–92 years), and an equal distribution
of male–female were included in the present study. Twenty-nine
samples displayed microsatellite instability (MSI), whereas 36 were
microsatellite-stable (MSS). All tumors were nonfamilial as assessed
by written questionnaires and cross check with the Norwegian Can-
cer Registry [17]. The colon, including the rectum, was divided into
proximal and distal sections: the proximal, or right side, spans from
cecum to two thirds of the way across transversum; the distal, or left
side, comprises the last third of the transversum, sigmoideum, and
the rectum. Of the 65 samples, 23 were located in the proximal
colon and 42 were located in the distal colon. The carcinomas are
from a prospective series collected from seven hospitals in the South-
east region of Norway during 1987–1989 and contain, on average,
84% tumor cells [18]. The tumors have been selected to achieve
a consistently higher number of MSI-positive tumors compared to
the normal distribution (15%). By stratifying the samples according
to the MSI status, we ensured that any results associated with the
MSI or MSS group would be detected.
NF1 Mutation Screening — DNA Amplification
and Denaturing High-Performance Liquid
Chromatography Analysis
Twenty-four representative CRC samples were analyzed for muta-
tions in the NF1 gene. These samples were selected to resemble the
remaining series with regards to sex, age, tumor location, MSI status,
and KRAS and BRAF mutation status. The 61 NF1 gene exons were
amplified in 61 polymerase chain reaction (PCR) fragments of 172
to 579 bp. The primers were generally positioned approximately 50
to 60 bp from the intron–exon boundary to allow the detection of
splicing defects while minimizing intronic polymorphisms. In total,
19,843 bases were screened per sample to obtain the final muta-
tion status. The dHPLC was carried out as previously published
[19], with minor alterations in the PCR protocol and denaturing
high-performance liquid chromatography (dHPLC) methods. For
details concerning the dHPLC, please refer to Table W1.
In short, the initial PCR was carried out in 25 μl of reaction vol-
umes and was cooled at room temperature for 60 minutes to yield
heteroduplex formation. The identification of somatic NF1 gene mu-
tations was carried out with dHPLC on a 3500HT WAVE DNA
fragment analysis system (Transgenomic, Crewe, UK) equipped with
a DNASep column (Transgenomic). Polymerase chain reaction pro-
ducts were examined through a 5% linear acetonitrile gradient for
heteroduplexes with a separation flow rate of 1.5 ml/min. Commer-
cially available WAVE Optimized Buffers (A, B, and D; Transgenomic)
and Syringe Solution (Transgenomic) were used to provide highly re-
producible retention times with WAVE System instrumentation. Res-
olution temperatures and starting concentrations of buffer B for
dHPLC analysis are reported in Table W1.
Sequencing
For each dHPLC abnormal elution profile, genomic DNA was
reamplified with dHPLC primers and directly sequenced in both di-
rections on a 3100 Genetic Analyzer (Applied Biosystems, Foster City,
CA). Forward and reverse sequences were analyzed and compared with
the mRNA reference sequence and with the chromosome 17 genomic
contig reference sequence (NM_000267). The first base (position +1)
of the initiator methionine is taken as the start of the cDNA. All mis-
sense and splicing mutations detected were absent on 200 control
chromosomes belonging to the unaffected subjects.2Sanger Institute — Catalogue of Somatic Mutations in Cancer (COSMIC) Web site.
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KRAS and BRAF Mutation Screening
The mutational hot spots of KRAS (exons 2 and 3) and BRAF
(exons 11 and 15) were directly sequenced in both directions for
all samples (n = 65) on an ABI PRISM 377 DNA Sequencer (Ap-
plied Biosystems) and an ABI PRISM 3730 DNA Sequencer (Ap-
plied Biosystems). All nucleotide numbers are based on the cDNA
reference sequence (BRAF, GenBank Accession No. NM_004333;
KRAS, GenBank Accession No. NM_004985). For primer details
please see Table W1.
Methylation-Specific PCR of RASSF1A
Methylation-specific PCR (MSP) of RASSF1A were performed
with published primers [20]. Polymerase chain reaction conditions
were as follows: denaturation and enzyme activation at 95°C for
15 minutes; 35 cycles of 30 seconds of denaturation at 95°C, 30 sec-
onds of annealing at 62°C, and 30 seconds of elongation at 72°C;
final extension at 72°C for 7 minutes.
Human placental DNA (Sigma Chemical Co., St. Louis, MO)
treated in vitro with SssI methyltransferase (New England Biolabs
Inc., Beverly, MA) was used as a positive control for MSP of meth-
ylated alleles, whereas DNA from normal lymphocytes was used as a
control for unmethylated alleles. The PCR products were separated
using a 2% agarose gel before individual visual scoring by two people.
Methylated samples with intensity equal to, or higher than, the posi-
tive control were considered to be hypermethylated.
Multiple Ligation-Dependent Probe Amplification Analysis
Screening for NF1 single- and multiexon deletions was carried out
in 24 of the colorectal carcinomas using the SALSA P081/082 NF1
(version 04, 05-02-2005) multiple ligation-dependent probe ampli-
fication (MLPA) assay (MRC Holland, Amsterdam, The Nether-
lands), as instructed by the manufacturer and previously reported
[21]. In brief, two probes in each exon were hybridized to the indi-
vidual tumor DNA, followed by a ligation of the nick between the
probes, and PCR amplification with 6-FAM–labeled universal pri-
mers. The amplified product was analyzed on an ABI PRISM
3100 Genetic Analyzer (Applied Biosystems), and the results were
exported to Coffalyzer v.5 Software (MRC Holland). As controls,
and in each experiment, we used five normal blood samples taken
from healthy individuals who do not show NF1 phenotypic traits
as determined by clinical evaluation. Furthermore, these controls
are verified to have an unaltered NF1, both at the nucleotide and
at the copy number level. A ratio of ∼1 should be obtained if both
alleles are present. A reduction or increase in the peak area values to
<0.7 or >1.3 was considered an indication of a deletion or a gain,
respectively. DNA samples showing a reduction or increase in the
MLPA peak area according to the chosen threshold values were re-
analyzed by MLPA, and only the samples showing consistent results
between the two experiments were scored as deleted or gained.
Real-Time Polymerase Chain Reaction
The gene gains identified by MLPA were also confirmed with a
TaqMan Real-Time PCR experiment using an ABI 7000 Sequence
Detection System (Applied Biosystems). Two TaqMan probes map-
ping in NF1 exons 25 and 28, respectively, were designed by File
Builder 3.1 software (Applied Biosystems). These were amplified sep-
arately together with the endogenous control (RNaseP) in 96-well fast
plates following the recommended protocol (Applied Biosystems). All
samples were analyzed in parallel, and the mean value was used for
data analysis. In cases where N -fold was below the maximum N -fold
copy number observed among the nondeleted DNA used as negative
controls, it was accepted that the test sample harbored one copy of
the target gene. In cases where N -fold resulted above the minimum
N -fold copy number observed among the nondeleted DNA, it was
accepted that the test sample harbored two or more copies of the tar-
get gene.
Statistics
For this study, 2 × 2 contingency tables were analyzed using Fisher’s
exact test, whereas 3 × 2 tables were analyzed by the Pearson chi-
square test. An independent t test was performed when comparing
continuous normally distributed data between two groups. All P val-
ues were derived from statistical tests using the SPSS Version 15.0
software (SPSS, Chicago, IL), and considered statistically significant
at P ≤ .05.
Results
NF1
One of the 24 carcinomas contained two missense mutations
(D1302Y and V2577G), the first located within the RAS-GRD domain.
In silico protein modeling showed that D1302Y has lost an ex-
posed negative charge, which may be important in protein folding
and in binding to other proteins. The V2577G most likely has no
effect on the neurofibromin function. Additional nine tumors dis-
played intronic mutations in the range of 4 to 57 bases away from
the intron–exon boundary (Table W2).
Using MLPA, we found that another 4 (17%) of 24 samples had a
gain of parts or of the whole gene, also confirmed with real-time
analysis (Table W2).
Comparison of the molecular results with clinicopathologic data
showed that 8 of 10 samples with exonic or intronic alterations in
NF1 occurred in MSI-positive tumors (P = .047), whereas 3 of 4 du-
plications occurred in MSS tumors.
KRAS
Direct sequencing of exons 2 and 3 of KRAS revealed that 26
(40%) of 65 tumors harbored a mutation (Table W2). All but two
mutations were missense mutations and occurred in codon 12, 13, or
61. These two were a 3-bp insertion (TGG) in exon 2 (c.49insTGG)
and a 3-bp deletion in exon 3, codons 62 to 63 (c.184_189delGAG;
Table W2). Furthermore, two of the tumors had two KRAS muta-
tions each. One displayed both G12A and V14I mutations, and
the second had both G12D and G13D.
Mutations in KRAS were seemingly more often present in MSS
tumors than in MSI tumors, 69% versus 46% (P = .08).
BRAF
Mutational analysis of BRAF gene revealed that 14 (22%) of 64
samples harbored a mutation. Eleven of these were the typical
V600E mutation; the remaining three were D594G, L597Q, and
G1406C (Table W2).
Mutations in BRAF were strongly associated to MSI, female gender,
and proximal location (P = .006, P = .015, and P = .025, respectively).
Figure 1 illustrates the individual localization of each mutation in
KRAS, BRAF, and NF1.
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RASSF1A
By MSP analysis, we found that 18 (31%) of 59 samples were hy-
permethylated in the promoter of RASSF1A. Methylation of the gene
was more frequent in the distally located tumors (P = .041), but was
not overlapping with the MSS phenotype. In eight tumors, hyper-
methylation of RASSF1A was the only observed alteration among the
four genes analyzed here. We found no covariance between RASSF1A
methylation and mutation status of either of the analyzed genes.
Dysregulation of RAS Signaling
When looking at concurrent mutations in individual tumors, we
found that KRAS and BRAF were mutually exclusive because all
BRAF mutations occurred in wild type KRAS tumors and vice versa
(P < .0001). The sample with NF1 missense mutations was MSI-
positive, proximally located, and harbored a BRAF mutation. When
including the intronic mutations in the number of NF1 mutations,
six of eight BRAF mutations occurred in NF1-mutated samples
Figure 1. Site distribution of mutations within each gene. The mutations for the respective gene are placed according to their sequence
position. In (a) and (b), only the exons in blue have been analyzed. In (c), all exons are analyzed, and the exons in orange indicate those
that are only expressed in isoforms. To the right, representative sequencing results of mutant samples are presented.
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(P = .03), overlapping with the MSI. Three of the four duplica-
tions found in the NF1 locus occurred in tumors with wild type
BRAF and KRAS. The remaining tumor had both a KRAS mutation
and duplication.
The occurrence of RASSF1A hypermethylation in the presence of
other mutations did not show any trends toward coexistence or mu-
tually exclusive nature.
Taken together, we found that 74% (48/65) of the tumors had an
overactive RAS signaling pathway due to change of at least one of the
four analyzed components (one alteration in 37/48, two alterations in
10/48, and three alterations in 1/48). For the 24 samples submitted for
complete analyses, the number of samples with at least one alteration
was 19 (79%): one alteration was seen in 14 samples, two alterations
were seen in 4 samples, and three alterations were seen in 1 sample. All
samples and alterations are summarized in Figure 2 and Table W2.
Discussion
This is the first report with an extensive analysis of the role of NF1
mutations in colorectal tumorigenesis. Previous mutation studies
have only looked at a small number of samples, usually in a limited
part of the gene, in the RAS–GAP domain. The initial mutational
report on NF1 showed that 1 of 22 colorectal adenocarcinomas har-
bored a mutation in the RAS–GAP domain using single-strand con-
formation polymorphism [9]. Another study of 10 colorectal cell
lines and 4 sporadic tumors using protein truncation test disclosed
mutations in the NF1 coding region in four MSI cell lines (40%)
and one MSI tumor (25%). Two of the cell lines had in fact two
mutations each [22]. A recent study examined five hereditary non-
polyposis CRC patients for mutations in five exons and found a mu-
tation in one (20%) of the patients who had a homozygous germline
mutation of MLH1 [23]. Moreover, loss of heterozygosity (LOH) at
loci within the NF1 gene have been shown in primary colorectal tu-
mors (range, 14–57%) [24,25]. One of these studies also used real-
time expression studies of NF1 in 55 of the carcinomas and found an
increased expression among tumors compared with normal colon tis-
sue. In the COSMIC database [26], 79 carcinomas of the colorectum
were apparently included among the NF1 data, yielding a mutation
frequency of 11%. However, seven of nine mutations reported were
from one study including seven cell lines, leaving only two of the mu-
tations occurring in sporadic primary tumors.
In this study, we found the NF1 mutation profile to be in contrast
to published germline mutation profile of NF1 patients3 as well as to
the somatic mutation profiles of malignant peripheral nerve sheath
tumor taken from patients with and without the NF1 disease [27,28]
(Bottillo I et al., unpublished observations). Furthermore, the median
age of the patients included in the present CRC series is old, suggest-
ing that potential NF1 carriers among them should have shown a
debut of an NF1-associated cancer type. As no typical NF1-associated
tumors are recorded, based on written questionnaires and confirma-
tion of cancer diagnoses from the Norwegian Cancer Registry [17],
it further support that the reported mutations are somatic. The ob-
served intronic mutations prevailing among the colorectal tumors
could be involved in alternative splicing but this remains to be eluci-
dated. Four of the nine intronic mutations were indels of one or two
bases in microsatellites and reflect replication slippage (which often oc-
curs in such repetitive stretches of bases) left unrepaired by the defec-
tive DNA mismatch repair system [29]. No such indels were found in
KRAS or BRAF.
Multiple ligation-dependent probe amplification results showed
that 17% of the analyzed samples had gained parts of or whole of
the NF1 gene. This is not in accordance with the expectations of a
tumor suppressor gene involved in tumorigenesis. A duplication of
NF1 could lead to a stronger negative regulation of KRAS, with sub-
sequent stronger control of proliferation and differentiation. The du-
plications may arise as a consequence of the chromosomal instability
present in three of the four tumors, which yield a wide range of gains
and losses of whole or parts of chromosomes. As reported by Ĉaĉev
et al. [30], colorectal tumors show a significant increase of NF1 mRNA
expression compared with corresponding normal tissue. They also
showed that the expression of NF1 isoform I (lacking exon 23a, located
in the middle of the RAS-GRD domain) was significantly higher in
tumor compared with normal tissue [30]. As of this, the present find-
ings are in agreement with those of the study by Ĉaĉev et al. [30].
We also found a 40% mutation frequency of KRAS, which is within
the expected range [26]. A mutated KRAS (in codons 12, 13, and 61)
hinders the hydrolysis of GTP to GDP, and will keep KRAS in a con-
stitutively active state, leading to phosphorylation of downstream effec-
tors such as BRAF [31]. BRAF mutations are known to be strongly
associated with MSI and CpG island methylator phenotype [32,33]
and are found very often mutated in sessile-serrated adenomas, lesions
often considered as a precursor of MSI-H tumors [34–38]. We found
BRAF mutation in 22% of the samples, a higher frequency than in
the mutation databases [26]. This reflects a bias due to the enrich-
ment of MSI tumors in the present series. In one study, 71% of the
MSI tumors had a V600E mutation in BRAF, as opposed to 7% in
the chromosomal-unstable tumors [39], a figure comparable with the
present series, as 18 (62%) of 29 of MSI tumors had BRAF muta-
tions. The most common BRAF mutation, V600E, just as the com-
mon KRAS mutations, will lead to a constitutively active protein, as
the activation loop of the protein is changed [31].
Figure 2. Alterations across the sample series. The pie chart indi-
cates the four analyzed components and the percentage of tu-
mors which showed alterations among these. Clockwise from
the wild type pie, we see alterations in RASSF1A and BRAF; BRAF;
BRAF and NF1; NF1; NF1 and KRAS; KRAS; KRAS and RASSF1A;
RASSF1A; RASSF1A, NF1 and BRAF. 3NF1 International Mutation Database (http://www.nfmutation.org).
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Some studies indicate an indirect interaction between RASSF1A
and KRAS through RASSF5 (previously annotated NORE1A)
[12], whereas others argue for a direct binding between RASSF1A
and activated, farnesylated, KRAS [11]. Previous studies have also
included RASSF1A when analyzing the impact of KRAS and BRAF
mutations in colorectal tumorigenesis [13,15,16,40], and none of
them found any co-occurrence between RASSF1A methylation and
BRAF or KRAS mutation, in line with the present finding.
When adding the data of the fourth component, NF1, of the RAS
signaling pathway, we found that more than 70% of the samples
had a hyperactive RAS signaling. As the effect of RASSF1A on
RAS signaling is still unclear, the eight samples with the sole alter-
ation being hypermethylation may not be important for an overac-
tive RAS signaling pathway. When we exclude the RASSF1A data
from the combined analysis, 62% (40/65) of the samples had an
overactive RAS signaling network, all due to KRAS or BRAF muta-
tions, as the sample with the NF1 missense mutations overlapped
with BRAF mutation. If we include the NF1 changes potentially af-
fecting the splicing, 77% of the tumors have a dysregulation of the
RAS signaling pathway.
In conclusion, we show that the RAS signaling network is exten-
sively dysregulated in colorectal carcinomas as more than 70% of the
tumors have an alteration in one or more of the four components.
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Table W1. Primer Sequences and dHPLC Conditions.
Exon Primer FW Primer RV Tm PCR (°C) Ampl. Size (bp) tdHPLC % B
1 5′-CTCCACAGACCCTCTCCTTG-3′ 5′-GGACAGAGTAGGTGAGGGGA-3′ 58 242 64–68 57–54
2 5′-AAACGTCATGATTTTCAATGGC-3′ 5′-GGGGAATTTGCTTTCTTTTCTT-3′ 58 281 55.5 56.6
3 5′-TTTCACTTTTCAGATGTGTGTTG-3′ 5′-CTTTGTGAATTTGATCTTGAG-3′ 58 210 55.5 54.8
4a 5′-GTTTGAAAATTTTCATAATAGAAA-3′ 5′-CTCACAGCAGCTTTGACCTCC-3′ 58 417 51–57 61–57
4b 5′-CAAGTGGTCCTCCTGCCTT-3′ 5′-GTCAAAAACTAGTATCATGAATG-3′ 58 283 55 55
4c 5′-TTTCCTAGCAGACAACTATCGA-3′ 5′-ATTTGCTGTTGTTAGCATCCT-3′ 62 308 54.5 57.5
5 5′-GAAGGAAGTTAGAAGTTTGTGACA-3′ 5′-ATGGCTGGTAAGGATACGATTG-3′ 62 172 54 51
6 5′-CATGTTTATCTTTTAAAAATGTTG-3′ 5′-ATGTGAAGCAGTTTATTTTACTCAA-3′ 62 332 54.5–56 58.6–56.6
7 5′-ATTTGCTATAATATTAGCTACATCTGG-3′ 5′-GTTGATAAGTTCATAGGACTTGCTTT-3′ 62 385 53–56.5 58–54.3
8 5′-GGATTTTACTGCCATTTGTGTG-3′ 5′-TATCTAACTATATTTACTGATGCTGTTA-3′ 58 276 56 56
9 5′-GCTGTTCTTTTTGGCTTC-3′ 5′-CCAAAAGGTATTGCTAAATTAC-3′ 58 183 54.5–56 52.2–49.7
9br 5′-GCTTAAAATTTGTATACAATAAAC-3′ 5′-CCTGGAGTGGTGCTTCATGCAT-3′ 58 193 55–60 52–48
10a 5′-CTACAGTGATAAACAGAGCAT-3′ 5′-ATTCCTGCTGCTTTGGTT-3′ 62 292 55–58 58–55
10a2 5′-CATTTTTTTGGTGTTTATGTATAGCAAG-3′ 5′-GTGTATAGTTACCATTATAGTCACATC-3′ 62 252 54–57–60.5 57–54–50
10b 5′-ATTATCCTGAGTCTTATGTC-3′ 5′-TCTCAAAATTATCACACTAAGTTA-3′ 58 229 54–57 56.2–51.2
10c 5′-ACCCTTTAGCAGTCACTGTC-3′ 5′-CTGTGAGTAACAGGTAGATG-3′ 58 307 54–59 59–54.4
11 5′-GAAAGAGCTCAATTTCTTAGC-3′ 5′-CACTTCCAAAGGTTTTATGGT-3′ 58 307 52–55 58–55
12a 5′-TGTATTCATTATGGGAGAATGCC-3′ 5′-TGGAAGAATATTTGGAATGGTAAT-3′ 58 269 54–56 56–54
12b 5′-GAGGTTTTTTAGGAGAGTCTC-3′ 5′-ATGTGCTCTGTTTGTTTTCTG-3′ 58 315 54–57.5 58–53.4
13 5′-CACAGTTTATTGCATTGTTAG-3′ 5′-CTGCCTCAAAGCACATGGC-3′ 62 380 57–61 59–54
14 5′-GCTCTTCCTACTCCTTTTGG-3′ 5′-TATGCCCTTAGCAACAGAAA-3′ 58 191 60 54
15 5′-ACTTGGCTGTAGCTGATTGA-3′ 5′-TCAAGAGTCGCTCAGTAAAGT-3′ 62 247 57 57
16 5′-CATTTTTTGTACTTTTGTCATGG-3′ 5′-CTCTTATTTTTCACCTTTCTC-3′ 58 579 55–58 63–60
17 5′-ATTTGGCTCTATGCCTGTGG-3′ 5′-ACTGCACACAAACTAGGGTG-3′ 58 385 55.5 58.8
18 5′-AGAAGTTGTGTACGTTCTTTTCT-3′ 5′-GCGGTTATTGGTAGAAAGGAG-3′ 58 367 53–56 57–54.4
19a 5′-TCATGTCACTTAGGTTATCTGG-3′ 5′-CCTTCAAGTATTAGTGGGTTTTA-3′ 58 242 55–57.5 58–55.7
19b 5′-TGAGGGGAAGTGAAAGAACT-3′ 5′-GCAAAAAGCAAATAAAGCC-3′ 58 236 53.5–57.5 56.5–52.5
20 5′-CCACCCTGGCTGATTATCG-3′ 5′-GCATGTAAGAGAAGCAAAAATTA-3′ 62 402 57–59 59–57
21 5′-AGCAAAAATTACTTCAGCAA-3′ 5′-TCAGAGCCAGAAGAAAGATG-3′ 58 393 57–59 59–57
22 5′-TGCTACTCTTTAGCTTCCTAC-3′ 5′-GGCTGATTGTCTTCTTTTAAGG-3′ 58 331 56.5–58 58.6–57
23.1 5′-TTTGTATCATTCATTTTGTGTGTA-3′ 5′-CTTTTCACATAGAACCGCTGTTTTTT-3′ 58 283 56–57 58.2–57.2
23.2 5′-GGCTTAATGTCTGTATA-3′ 5′-GAGATTACCATTATTAATCTAAAGT-3′ 58 270 53–59 57–51.3
23a 5′-AGCCAGAAATAGTAGACATGATTGGG-3′ 5′-TCTACTAATTCTGGCACAAAATAG-3′ 62 446 54.5 60.3
24 5′-TTGAACTCTTTGTTTTCATGTCTT-3′ 5′-GATAATCTAGCTATCTTAAATTCC-3′ 58 266 53–58 57–52.1
25 5′-AATTTATAGAATGAGGAATG-3′ 5′-GTACCTGTTTTACATGAAGTTCCT-3′ 54 335 52–54–57 58–56–53.7
26 5′-GCTTTGTCTAATGTCAAGTCA-3′ 5′-GATAGTGAACACTCTCCGTTTAA-3′ 62 342 56–58 58–54
27a 5′-ATGGTCCTGAGGTCTTTTTG-3′ 5′-GCCACCAGGCCACTTGTTAG-3′ 62 361 57 59
27b 5′-TTGCTTTTAAAATATTTTTTCATTTTAG-3′ 5′-CCCAGTTGACTTAACAGGAATT-3′ 58 330 55 55
28 5′-AAAATAAAATTGATTAGTGGCATCTG-3′ 5′-AAATGTCACGTAAGGCTGTCG-3′ 62 636 55–58 62–60
29 5′-TCTGGAGCCTTTTAGAATTTTATGT-3′ 5′-TCAGTTTGATTTGGGGTTTGTTGC-3′ 62 460 58–60.5 60–55.5
30 5′-GAAAAAATTTTGGAACTATAAGG-3′ 5′-TAACAATTATTCTAAGAGAATTCAAAG-3′ 58 322 51–56.5 58–54
31 5′-TTTTTTCCCCGAATTCTTTATG-3′ 5′-CTTCAGAAAGCATGTAGACACTCAC-3′ 58 425 55–57 61–59
32 5′-ATCTAGTATTTTTGAGGCCTCAG-3′ 5′-CCTTCTGTACTATAGCATATCTG-3′ 58 312 53–56 58–55
33 5′-TGCTAAAACTTTGAGTCCCATG-3′ 5′-GTGCTCTAACACCAAGTTGC-3′ 64 448 56–59 59–53.8
34 5′-TTCTAAATTCAAAATGAAACATGG-3′ 5′-AAAAACACTTGCATGGACTG-3′ 58 432 51.5–57 60–55
35 5′-GCATGGACTGTGTTATTGGTA-3′ 5′-TCTGTGGATCTTTTAATTGCA-3′ 58 319 53.5 56.8
36 5′-GCTGGACCAGTGGACAGAAC-3′ 5′-GACGTTTAAATTTGAGGTCAATGA-3′ 62 389 53–58 57.8–54.3
37 5′-TCCTGAATTCATTCCGAGATT-3′ 5′-TCATTTTGGGTATCAGTGTTGAA-3′ 58 237 54–56 55.5–53.5
38 5′-AACTGCAGTGTGTTTTGAAAGAG-3′ 5′-GAGGTTCCTAGATTACTCAAATTTAG-3′ 62 257 57–60 56–53
39 5′-TTGAACACAAAATTAAGTGAGCC-3′ 5′-GAAGTAAGTTAGCCCTTATGTCTTAC-3′ 62 318 56 55
40 5′-ATTCACATTCACATATGCATGTTTTACCTTC-3′ 5′-CTTTGGTTCAAGACACTACAG-3′ 62 547 55–56 61.6–61.1
41 5′-GTGCACATTTAACAGGTACTAT-3′ 5′-ATCTAGAGATGGCCTAGGAAG-3′ 62 373 55.5 58
42 5′-CTTGGAAGGAGCAAACGATGGTTG-3′ 5′-CCATGTCAGTGTAGCAAAGTTTTTG-3′ 58 356 55–60 56–52.2
43 5′-AGTGTATTCCCATTTATAGACACTG-3′ 5′-CATTGAAAATAAGGTGGGAGA-3′ 58 234 55–57.5 56–52.4
44 5′-GAAGTAACATTGAAATAGTTAGG-3′ 5′-TCCAGTCTACTTTTAGGAGGCC-3′ 58 271 58.5 55
45 5′-CATGAATAGGATACAGTCTTCTAC-3′ 5′-GTTAAATGCTTACCCAGTAATGTG-3′ 62 269 57 56
46 5′-CTCATCTCCCTTTAATTTTGGC-3′ 5′-TCTGGAGAAGGATGGTTGATG-3′ 58 295 54–56.5 57–55.1
47 5′-CTGTTACAATTAAAAGATACCTTG-3′ 5′-GTATGCCTGCTTTAAGAACACACA-3′ 62 185 55.5 51.4
48 5′-AAGGAAGAAAAATAGTAAATTAAGTCC-3′ 5′-GTTTATAGCAAATTTTGCTCCTT-3′ 58 423 53–58 61–56.9
48a 5′-ATTCAATAATTAAAACCAGATTCC-3′ 5′-CTTTAGGAACTTGTAAAGCCACC-3′ 58 327 54 58
49 5′-AGAATGTGTCCCCGTTGTTAA-3′ 5′-TAATGAACCCATCCGGTTTG-3′ 58 369 58.5 58.4
KRAS ex2 5′-ACTGGTGGAGTATTTGATA-3′ 5′-GTATCAAAGAATGGTCCT-3′ 50 — — —
KRAS ex3 5′-ATAATAGCCAATCCTAA-3′ 5′-ATGGCATTAGCAAAG-3′ 53 — — —
BRAF ex11 5′-TCATAATGCTTGCTCTGATAGGA-3′ 5′-GGCCAAAAATTTAATCAGTGGA-3′ 60 — — —
BRAF ex15 5′-TCCCTCTCAGGCATAAGGTAA-3′ 5′-CGAACAGTGAATATTTCCTTTGAT-3′ 58 — — —
Tm PCR, indicates PCR melting temperature (°C); Ampl. Size, amplicon size; tdHPLC, range in temperature used with high-performance liquid chromatography; % B, starting concentration for buffer B
used in dHPLC.
Table W2. Detailed Somatic Events of Four Components in the MAPK Pathway.
Tumor ID MSI Status KRASmut BRAFmut NF1mut MLPA Real-time RASSF1A
848 MSI WT WT NP NP U
854 MSI c.184-189delGAG WT NP NP U
884 MSI WT V600E D1302Y/V2577G WT U
894 MSI c.49insTTG WT NP NP U
910 MSI WT WT c.(3114-50)delTG WT U
912 MSI G13D WT NP NP U
955 MSI WT V600E NP NP U
965 MSI WT V600E NP NP U
980 MSI WT V600E WT WT U
984 MSI WT V600E WT WT U
988 MSI WT WT NP NP ND
1022 MSI WT WT NP NP U
1044 MSI WT V600E c.480-57C>T WT U
1047 MSI G12A/V14I WT WT WT M
1066 MSI WT WT WT WT M
1117 MSI WT WT NP NP U
1132 MSI G12V WT NP NP U
1141 MSI WT WT NP NP U
1190 MSI WT V600E NP NP M
1193 MSI WT V600E c.7395-7C>T WT U
1268 MSI WT V600E Ex3+24G>A WT U
1273 MSI WT V600E c.(1392+46_+53)delTT WT U
1314 MSI WT WT NP NP U
1326 MSI G13D WT c.(1392+46_+53)delT WT U
1341 MSI WT V600E c.(61-4_-12)delT WT M
1349 MSI WT WT NP NP M
1363 MSI G13D WT WT Gain of IVS27b-Ex49 1.66 U
1388A MSI WT WT NP NP M
1388C MSI G13D WT NP NP M
868 MSS WT WT NP NP U
886 MSS G12D WT NP NP U
887 MSS G12C WT NP NP M
896 MSS WT WT WT Gain of whole gene 1.59 M
904 MSS WT WT NP NP U
922 MSS G12V WT NP NP U
923 MSS G13D WT NP NP U
927 MSS G12V WT NP NP M
946 MSS WT WT NP NP U
948 MSS G12R WT NP NP U
953 MSS WT WT WT WT U
966 MSS Q61L WT NP NP U
974 MSS G12A WT NP NP U
976 MSS G12D WT NP NP M
1013 MSS WT D594G NP NP U
1024 MSS G12C WT NP NP U
1027 MSS G13D WT NP NP U
1029 MSS G12D WT NP NP U
1046 MSS WT WT NP NP U
1060 MSS WT WT NP NP M
1069 MSS WT WT NP NP U
1103 MSS WT WT WT Gain of whole gene 1.25 U
1111 MSS WT WT NP NP M
1121 MSS G12A WT WT WT M
1124 MSS G12D/G13D WT WT WT ND
1166 MSS G13D WT WT WT M
1167 MSS WT WT WT Gain of whole gene 1.67 M
1194 MSS WT WT NP NP M
1197 MSS WT WT NP NP ND
1287 MSS WT WT c.2252-31A>G WT ND
1294 MSS WT G469R NP NP U
1296 MSS G13D WT WT WT U
1340 MSS WT WT WT WT ND
1364 MSS WT L597Q NP NP M
1369 MSS G12D ND NP NP ND
1391 MSS G12D WT c.2252-31A>T WT U
